Naltrekson: Perbedaan antara revisi

Jelajahi riwayat secara interaktif

← Revisi sebelumnya

Konten dihapus Konten ditambahkan

VisualTeks wiki

Revisi per 11 Februari 2024 08.32 sunting WanaraLima (bicara \| kontrib) 1.697 suntingan Artikel baru tentang topik farmasi yang masih memerlukan tambahan dan pengembangan. Artikel ini merupakan terjemahan wikipedia bahasa Inggris masih perlu ditinjau ulang juga disesuaikan dengan padanan bahasa Indonesia Tag: halaman dengan galat kutipan VisualEditor ← Revisi sebelumnya		Revisi terkini sejak 22 November 2024 15.02 sunting balikkan Muhammad Anas Sidik (bicara \| kontrib) 23.705 suntingan k Muhammad Anas Sidik memindahkan halaman Naltrexone ke Naltrekson: Judul salah eja Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan
(4 revisi perantara oleh 4 pengguna tidak ditampilkan)
Baris 48: <!-- Pharmacokinetic data --> \| bioavailability = 5–60%<ref name="pmid2836152">{{cite journal \|last1=Gonzalez \|first1=JP \|last2=Brogden \|first2=RN \|title=Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. \|journal=Drugs \|date=Maret 1988 \|volume=35 \|issue=3 \|pages=192-213 \|doi=10.2165/00003495-198835030-00002 \|pmid=2836152}}</ref><ref name="pmid19537999">{{cite journal \|last1=Lee \|first1=MW \|last2=Fujioka \|first2=K \|title=Naltrexone for the treatment of obesity: review and update. \|journal=Expert opinion on pharmacotherapy \|date=Agustus 2009 \|volume=10 \|issue=11 \|pages=1841-5 \|doi=10.1517/14656560903048959 \|pmid=19537999}}</ref> ~~\| bioavailability = 5–60%<ref name="pmid2836152" /><ref name="pmid19537999" />~~ \| protein_bound = 20%<ref name="pmid2836152" /><ref name="ReviaLabel" /> \| metabolism = [[Liver]] (non-[[cytochrome P450\|CYP450]])<ref name="SevarinoKosten2009">{{cite book \| veditors = Dean RL, Bilsky EJ, Negus SS \| title = Opiate Receptors and Antagonists \| vauthors = Sevarino KA, Kosten TR \| chapter = Naltrexone for Initiation and Maintenance of Opiate Abstinence \| date = 2009 \| pages = ~~227–245~~[https://archive.org/details/opiatereceptorsa0000unse/page/227 227]–245 \| publisher = Humana Press \| doi = 10.1007/978-1-59745-197-0_12 \| isbn = 978-1-58829-881-2\| url = https://archive.org/details/opiatereceptorsa0000unse}}</ref> \| metabolites = [[6β-Naltrexol]], others<ref name="pmid2836152" /> \| onset = 30 minutes<ref name=AHFS2017/> Baris 100: }} '''Naltrexone''' adalah [[Medikasi\|obat]] yang digunakan untuk mengatasi individu yang mengalami ketergantungan alkohol ataupun opioid . <ref name="AHFS2017"><cite class="citation web cs1"><span class="cx-segment" data-segmentid="252">[https://www.drugs.com/monograph/naltrexone.html "Naltrexone Monograph for Professionals - Drugs.com"]. </span><span class="cx-segment" data-segmentid="253">''Drugs.com''. </span><span class="cx-segment" data-segmentid="254">American Society of Health-System Pharmacists. </span><span class="cx-segment" data-segmentid="255">[https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html Archived] from the original on 9 November 2017<span class="reference-accessdate">. </span></span><span class="cx-segment" data-segmentid="256"><span class="reference-accessdate">Retrieved <span class="nowrap">9 November</span> 2017</span>.</span></cite></ref> Untuk penggunaan obat ini pada individu ketergantungan obat golongan opioid direkomendasikan untuk melakukan detoksifikasi. <ref name="AHFS2017"~~>{{cite~~ ~~web\|title=Naltrexone Monograph for Professionals - Drugs.com\|url=https:~~//www.drugs.com/monograph/naltrexone.html\|website=Drugs.com\|publisher=American Society of Health-System Pharmacists\|access-date=9 November 2017\|url-status=live\|archive-url=https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html\|archive-date=9 November 2017}}</ref> Rute pemberian obat ini melalui oral dan melalui [[penyuntikan intraotot]] . <ref name="AHFS2017"~~>{{cite~~ ~~web\|title=Naltrexone Monograph for Professionals - Drugs.com\|url=https:~~//www.drugs.com/monograph/naltrexone.html\|website=Drugs.com\|publisher=American Society of Health-System Pharmacists\|access-date=9 November 2017\|url-status=live\|archive-url=https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html\|archive-date=9 November 2017}}</ref> Efek terapi membutuhkan waktu 30 menit. <ref name="AHFS2017"~~>{{cite~~ ~~web\|title=Naltrexone Monograph for Professionals - Drugs.com\|url=https:~~//www.drugs.com/monograph/naltrexone.html\|website=Drugs.com\|publisher=American Society of Health-System Pharmacists\|access-date=9 November 2017\|url-status=live\|archive-url=https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html\|archive-date=9 November 2017}}</ref> Kejadian efek samping yang mungkin bisa muncul yakni[[insomnia]], [[kegelisahan]], [[Mual\|rasa mual]], dan juga [[sakit kepala]] . <ref name="AHFS2017"~~><cite~~ ~~class="citation web cs1"><span class="cx-segment" data-segmentid="252">[https:~~//www.drugs.com/monograph/naltrexone.html "Naltrexone Monograph for Professionals - Drugs.com"]. </span><span class="cx-segment" data-segmentid="253">''Drugs.com''. </span><span class="cx-segment" data-segmentid="254">American Society of Health-System Pharmacists. </span><span class="cx-segment" data-segmentid="255">[https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html Archived] from the original on 9 November 2017<span class="reference-accessdate">. </span></span><span class="cx-segment" data-segmentid="256"><span class="reference-accessdate">Retrieved <span class="nowrap">9 November</span> 2017</span>.</span></cite></ref> Pada individu yang masih menggunakan obat-obatan opioid, bisa mengalami sindrom penghentian opioid. <ref name="AHFS2017"~~>{{cite~~ ~~web\|title=Naltrexone Monograph for Professionals - Drugs.com\|url=https:~~//www.drugs.com/monograph/naltrexone.html\|website=Drugs.com\|publisher=American Society of Health-System Pharmacists\|access-date=9 November 2017\|url-status=live\|archive-url=https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html\|archive-date=9 November 2017}}</ref> Untuk penderita gagal hati tidak direkomendasikan untuk menggunakan obat ini. <ref name="AHFS2017"~~>{{cite~~ ~~web\|title=Naltrexone Monograph for Professionals - Drugs.com\|url=https:~~//www.drugs.com/monograph/naltrexone.html\|website=Drugs.com\|publisher=American Society of Health-System Pharmacists\|access-date=9 November 2017\|url-status=live\|archive-url=https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html\|archive-date=9 November 2017}}</ref> Penggunaan untuk ibu [[Kehamilan\|hamil]] masih belum diketahui tingkat keamanannya. <ref name="AHFS2017"~~>{{cite~~ ~~web\|title=Naltrexone Monograph for Professionals - Drugs.com\|url=https:~~//www.drugs.com/monograph/naltrexone.html\|website=Drugs.com\|publisher=American Society of Health-System Pharmacists\|access-date=9 November 2017\|url-status=live\|archive-url=https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html\|archive-date=9 November 2017}}</ref> <ref>{{Cite journal\|date=July 2017\|title=Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women\|journal=Pharmacotherapy\|volume=37\|issue=7\|pages=824–839\|doi=10.1002/phar.1958\|pmid=28543191\|vauthors=Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ}}</ref> Naltrexone merupakan golongan antagonis opioid dan memiliki mekanisme kerja dengan cara memblokir efek opioid, baik yang [[Endorfin\|berasal dari dalam]] maupun luar tubuh. <ref name="AHFS2017"~~>{{cite~~ ~~web\|title=Naltrexone Monograph for Professionals - Drugs.com\|url=https:~~//www.drugs.com/monograph/naltrexone.html\|website=Drugs.com\|publisher=American Society of Health-System Pharmacists\|access-date=9 November 2017\|url-status=live\|archive-url=https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html\|archive-date=9 November 2017}}</ref> Obat ini pertama kali dibuat di tahun 1965 dan disetujui untuk penggunaannya secara medis di Amerika Serikat di tahun 1984. <ref name="AHFS2017"~~><cite~~ class="citation web cs1"><span class="cx-segment" data-segmentid="252">[https://www.drugs.com/monograph/naltrexone.html "Naltrexone Monograph for Professionals - Drugs.com"]. </span><span class="cx-segment" data-segmentid="253">''Drugs.com''. </span><span class="cx-segment" data-segmentid="254">American Society of Health-System Pharmacists. </span><span class="cx-segment" data-segmentid="255">[https://web.archive.org/web/20171109134845/https://www.drugs.com/monograph/naltrexone.html Archived] from the original on 9 November 2017<span class="reference-accessdate">. </span></span><span class="cx-segment" data-segmentid="256"><span class="reference-accessdate">Retrieved <span class="nowrap">9 November</span> 2017</span>.</span></cite></~~ref~~> <ref name="Sad2012">{{Cite book\|last=Sadock\|first=Benjamin J.\|last2=Sadock\|first2=Virginia A.\|last3=Sussman\|first3=Norman\|date=2012\|url=https://books.google.ca/books?id=qp-H3UruKvIC&pg=PT265\|title=Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment\|publisher=Lippincott Williams & Wilkins\|isbn=9781451154467\|page=265\|language=en\|archive-url=https://web.archive.org/web/20171205042100/https://books.google.ca/books?id=qp-H3UruKvIC&pg=PT265\|archive-date=2017-12-05\|url-status=live}}</ref> Obat ini masuk ke dalam [[Daftar Obat Esensial Organisasi Kesehatan Dunia]] . == Referensi == [[Kategori:Obat Esensial Organisasi Kesehatan Dunia]] [[Kategori:~~Obat~~Siklopropana]] [[Kategori:~~Farmasi~~Antagonis reseptor delta-opioid]] [[Kategori:Hepatotoksin]] [[Kategori:4,5-Epoksimorfinan]] [[Kategori:Keton]] [[Kategori:Antagonis reseptor mu-opioid]] [[Kategori:Fenol]] <references />{{Farmasi-stub}}